Table of Contents

Research Articles: Therapeutics, Targets, and Development

• Research Articles: Therapeutics, Targets, and Development

  Laser postionization secondary neutral mass spectrometry in tissue: a powerful tool for elemental and molecular imaging in the development of targeted drugs

  Andrea Wittig, Heinrich F. Arlinghaus, Christian Kriegeskotte, Raymond L. Moss, Klaas Appelman, Kurt W. Schmid and Wolfgang A.G. Sauerwein

  Mol Cancer Ther July 1 2008 7 (7) 1763-1771; DOI:10.1158/1535-7163.MCT-08-0191

  
  
• Research Articles: Therapeutics, Targets, and Development

  Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair

  Mahmoud Toulany, Rainer Kehlbach, Urszula Florczak, Ali Sak, Shaomeng Wang, Jianyong Chen, Markus Lobrich and H. Peter Rodemann

  Mol Cancer Ther July 1 2008 7 (7) 1772-1781; DOI:10.1158/1535-7163.MCT-07-2200

  
  
• Research Articles: Therapeutics, Targets, and Development

  eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling

  Alpana Soni, Argun Akcakanat, Gopal Singh, David Luyimbazi, Yuhuan Zheng, Doyil Kim, Ana Gonzalez-Angulo and Funda Meric-Bernstam

  Mol Cancer Ther July 1 2008 7 (7) 1782-1788; DOI:10.1158/1535-7163.MCT-07-2357

  
  
• Research Articles: Therapeutics, Targets, and Development

  Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways

  Tingfang Yi, Sung-Gook Cho, Zhengfang Yi, Xiufeng Pang, Melissa Rodriguez, Ying Wang, Gautam Sethi, Bharat B. Aggarwal and Mingyao Liu

  Mol Cancer Ther July 1 2008 7 (7) 1789-1796; DOI:10.1158/1535-7163.MCT-08-0124

  
  
• Research Articles: Therapeutics, Targets, and Development

  Antiproliferative effect of sulindac in colonic neoplasia prevention: role of COOH-terminal Src kinase

  Dhananjay P. Kunte, Ramesh K. Wali, Jennifer L. Koetsier and Hemant K. Roy

  Mol Cancer Ther July 1 2008 7 (7) 1797-1806; DOI:10.1158/1535-7163.MCT-08-0022

  
  
• Research Articles: Therapeutics, Targets, and Development

  Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma

  Hui Guan, Zhichao Zhou, Gary E. Gallick, Shu-Fang Jia, Jaime Morales, Anil K. Sood, Seth J. Corey and Eugenie S. Kleinerman

  Mol Cancer Ther July 1 2008 7 (7) 1807-1816; DOI:10.1158/1535-7163.MCT-08-0058

  
  
• Research Articles: Therapeutics, Targets, and Development

  Silibinin inhibits cytokine-induced signaling cascades and down-regulates inducible nitric oxide synthase in human lung carcinoma A549 cells

  Manesh Chittezhath, Gagan Deep, Rana P. Singh, Chapla Agarwal and Rajesh Agarwal

  Mol Cancer Ther July 1 2008 7 (7) 1817-1826; DOI:10.1158/1535-7163.MCT-08-0256

  
  
• Research Articles: Therapeutics, Targets, and Development

  Active roles for inhibitory κB kinases α and β in nuclear factor-κB–mediated chemoresistance to doxorubicin

  Brian K. Bednarski, Xiaoyu Ding, Kavita Coombe, Albert S. Baldwin and Hong J. Kim

  Mol Cancer Ther July 1 2008 7 (7) 1827-1835; DOI:10.1158/1535-7163.MCT-08-0321

  
  
• Research Articles: Therapeutics, Targets, and Development

  Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models

  Dimitri Pchejetski, Nicolas Doumerc, Muriel Golzio, Maria Naymark, Justin Teissié, Takafumi Kohama, Jonathan Waxman, Bernard Malavaud and Olivier Cuvillier

  Mol Cancer Ther July 1 2008 7 (7) 1836-1845; DOI:10.1158/1535-7163.MCT-07-2322

  
  
• Research Articles: Therapeutics, Targets, and Development

  Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells

  Dongwei Zhang, Ashutosh Pal, William G. Bornmann, Fumiyuki Yamasaki, Francisco J. Esteva, Gabriel N. Hortobagyi, Chandra Bartholomeusz and Naoto T. Ueno

  Mol Cancer Ther July 1 2008 7 (7) 1846-1850; DOI:10.1158/1535-7163.MCT-08-0168

  
  
• Research Articles: Therapeutics, Targets, and Development

  Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

  Sauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen, Pascal Furet, Christian Schnell, Christine Fritsch, Saskia Brachmann, Patrick Chène, Alain De Pover, Kevin Schoemaker, Doriano Fabbro, Daniela Gabriel, Marjo Simonen, Leon Murphy, Peter Finan, William Sellers and Carlos García-Echeverría

  Mol Cancer Ther July 1 2008 7 (7) 1851-1863; DOI:10.1158/1535-7163.MCT-08-0017

  
  
• Research Articles: Therapeutics, Targets, and Development

  Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation

  Atsushi Tomioka, Motoyoshi Tanaka, Marco A. De Velasco, Satoshi Anai, Satoshi Takada, Toshihiro Kushibiki, Yasuhiko Tabata, Charles J. Rosser, Hirotsugu Uemura and Yoshihiko Hirao

  Mol Cancer Ther July 1 2008 7 (7) 1864-1870; DOI:10.1158/1535-7163.MCT-07-2198

  
  
• Research Articles: Therapeutics, Targets, and Development

  A novel combination: ranpirnase and rosiglitazone induce a synergistic apoptotic effect by down-regulating Fra-1 and Survivin in cancer cells

  Maria E. Ramos-Nino and Benjamin Littenberg

  Mol Cancer Ther July 1 2008 7 (7) 1871-1879; DOI:10.1158/1535-7163.MCT-08-0308

  
  
• Research Articles: Therapeutics, Targets, and Development

  Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

  Andrea J. Gonzales, Kenneth E. Hook, Irene W. Althaus, Paul A. Ellis, Erin Trachet, Amy M. Delaney, Patricia J. Harvey, Teresa A. Ellis, Danielle M. Amato, James M. Nelson, David W. Fry, Tong Zhu, Cho-Ming Loi, Stephen A. Fakhoury, Kevin M. Schlosser, Karen E. Sexton, R. Thomas Winters, Jessica E. Reed, Alex J. Bridges, Daniel J. Lettiere, Deborah A. Baker, Jianxin Yang, Helen T. Lee, Haile Tecle and Patrick W. Vincent

  Mol Cancer Ther July 1 2008 7 (7) 1880-1889; DOI:10.1158/1535-7163.MCT-07-2232

  
  
• Research Articles: Therapeutics, Targets, and Development

  Single-chain antibody/activated BID chimeric protein effectively suppresses HER2-positive tumor growth

  Xiu-Chun Qiu, Yan-Ming Xu, Fang Wang, Qing-Yu Fan, Li-Feng Wang, Bao-An Ma, Lin-Tao Jia, Jing Zhao, Yan-Ling Meng, Li-Bo Yao, Si-Yi Chen and An-Gang Yang

  Mol Cancer Ther July 1 2008 7 (7) 1890-1899; DOI:10.1158/1535-7163.MCT-07-2235

  
  
• Research Articles: Therapeutics, Targets, and Development

  Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer

  Danica L. Rowe, Tuba Ozbay, Laura M. Bender and Rita Nahta

  Mol Cancer Ther July 1 2008 7 (7) 1900-1908; DOI:10.1158/1535-7163.MCT-08-0012

  
  
• Research Articles: Therapeutics, Targets, and Development

  c-Jun knockdown sensitizes osteosarcoma to doxorubicin

  Crispin R. Dass, Levon M. Khachigian and Peter F.M. Choong

  Mol Cancer Ther July 1 2008 7 (7) 1909-1912; DOI:10.1158/1535-7163.MCT-08-0086

  
  
• Research Articles: Therapeutics, Targets, and Development

  Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis

  Laura P. Stabile, Mary E. Rothstein, Phouthone Keohavong, Jide Jin, Jinling Yin, Stephanie R. Land, Sanja Dacic, The Minh Luong, K. Jin Kim, Austin M. Dulak and Jill M. Siegfried

  Mol Cancer Ther July 1 2008 7 (7) 1913-1922; DOI:10.1158/1535-7163.MCT-07-2169

  
  
• Research Articles: Therapeutics, Targets, and Development

  Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model

  Akihiko Miyanaga, Akihiko Gemma, Rintaro Noro, Kiyoko Kataoka, Kuniko Matsuda, Michiya Nara, Tetsuya Okano, Masahiro Seike, Akinobu Yoshimura, Akiko Kawakami, Haruka Uesaka, Hiroki Nakae and Shoji Kudoh

  Mol Cancer Ther July 1 2008 7 (7) 1923-1930; DOI:10.1158/1535-7163.MCT-07-2140

  
  
• Research Articles: Therapeutics, Targets, and Development

  Array-based analysis of the effects of trichostatin A and CG-1521 on cell cycle and cell death in LNCaP prostate cancer cells

  Somdutta Roy, Randy Jeffrey and Martin Tenniswood

  Mol Cancer Ther July 1 2008 7 (7) 1931-1939; DOI:10.1158/1535-7163.MCT-07-2353

  
  
• Research Articles: Therapeutics, Targets, and Development

  Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis

  Marianne Kraus, Elke Malenke, Jeannette Gogel, Holger Müller, Thomas Rückrich, Herman Overkleeft, Huib Ovaa, Ewa Koscielniak, Jörg Thomas Hartmann and Christoph Driessen

  Mol Cancer Ther July 1 2008 7 (7) 1940-1948; DOI:10.1158/1535-7163.MCT-07-2375

  
  
• Research Articles: Therapeutics, Targets, and Development

  Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-κB and activator protein-1 related mechanisms

  Zhong Chen, Justin L. Ricker, Pramit S. Malhotra, Liesl Nottingham, Lorena Bagain, Tin Lap Lee, Ning T. Yeh and Carter Van Waes

  Mol Cancer Ther July 1 2008 7 (7) 1949-1960; DOI:10.1158/1535-7163.MCT-07-2046

  
  
• Research Articles: Therapeutics, Targets, and Development

  Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity

  Richard Sullivan, Geneviève C. Paré, Lisa J. Frederiksen, Gregg L. Semenza and Charles H. Graham

  Mol Cancer Ther July 1 2008 7 (7) 1961-1973; DOI:10.1158/1535-7163.MCT-08-0198

  
  
• Research Articles: Therapeutics, Targets, and Development

  Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1α and -2α

  Maura Puppo, Florinda Battaglia, Catherine Ottaviano, Silvana Delfino, Domenico Ribatti, Luigi Varesio and Maria Carla Bosco

  Mol Cancer Ther July 1 2008 7 (7) 1974-1984; DOI:10.1158/1535-7163.MCT-07-2059

  
  
• Research Articles: Therapeutics, Targets, and Development

  HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair

  Thuy T. Koll, Steven S. Feis, Mollie H. Wright, Modupe M. Teniola, Mekel M. Richardson, Ana I. Robles, John Bradsher, Jacek Capala and Lyuba Varticovski

  Mol Cancer Ther July 1 2008 7 (7) 1985-1992; DOI:10.1158/1535-7163.MCT-07-2104

  
  
• Research Articles: Therapeutics, Targets, and Development

  S1P differentially regulates migration of human ovarian cancer and human ovarian surface epithelial cells

  Dongmei Wang, Zhenwen Zhao, Andrea Caperell-Grant, Gong Yang, Samuel C. Mok, Jinsong Liu, Robert M. Bigsby and Yan Xu

  Mol Cancer Ther July 1 2008 7 (7) 1993-2002; DOI:10.1158/1535-7163.MCT-08-0088

  
  
• Research Articles: Therapeutics, Targets, and Development

  Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase

  Tatiana Okouneva, Olga Azarenko, Leslie Wilson, Bruce A. Littlefield and Mary Ann Jordan

  Mol Cancer Ther July 1 2008 7 (7) 2003-2011; DOI:10.1158/1535-7163.MCT-08-0095

  
  
• Research Articles: Therapeutics, Targets, and Development

  Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration

  Gang-Ming Zou and Anirban Maitra

  Mol Cancer Ther July 1 2008 7 (7) 2012-2021; DOI:10.1158/1535-7163.MCT-08-0113

  
  
• Research Articles: Therapeutics, Targets, and Development

  Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression

  Jimmy M-M. Kwok, Stephen S. Myatt, Charles M. Marson, R. Charles Coombes, Demetra Constantinidou and Eric W-F. Lam

  Mol Cancer Ther July 1 2008 7 (7) 2022-2032; DOI:10.1158/1535-7163.MCT-08-0188

  
  
• Research Articles: Therapeutics, Targets, and Development

  Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity

  Lourdes Roque-Navarro, Krittalak Chakrabandhu, Joel de León, Sandra Rodríguez, Carlos Toledo, Adriana Carr, Cristina Mateo de Acosta, Anne-Odile Hueber and Rolando Pérez

  Mol Cancer Ther July 1 2008 7 (7) 2033-2041; DOI:10.1158/1535-7163.MCT-08-0222

  
  
• Research Articles: Therapeutics, Targets, and Development

  Chemoprevention by perillyl alcohol coupled with viral gene therapy reduces pancreatic cancer pathogenesis

  Irina V. Lebedeva, Zhao-zhong Su, Nichollaq Vozhilla, Lejuan Chatman, Devanand Sarkar, Paul Dent, Mohammad Athar and Paul B. Fisher

  Mol Cancer Ther July 1 2008 7 (7) 2042-2050; DOI:10.1158/1535-7163.MCT-08-0245

  
  
• Research Articles: Therapeutics, Targets, and Development

  Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968

  Claudio Pisano, Michelandrea De Cesare, Giovanni Luca Beretta, Valentina Zuco, Graziella Pratesi, Sergio Penco, Loredana Vesci, Rosanna Foderà, Fabiana Fosca Ferrara, Mario Berardino Guglielmi, Paolo Carminati, Sabrina Dallavalle, Gabriella Morini, Lucio Merlini, Augusto Orlandi and Franco Zunino

  Mol Cancer Ther July 1 2008 7 (7) 2051-2059; DOI:10.1158/1535-7163.MCT-08-0266

  
  
• Research Articles: Therapeutics, Targets, and Development

  Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone

  Pawan Kumar, Qinghong Gao, Yu Ning, Zhuo Wang, Paul H. Krebsbach and Peter J. Polverini

  Mol Cancer Ther July 1 2008 7 (7) 2060-2069; DOI:10.1158/1535-7163.MCT-08-0287

  
  
• Research Articles: Therapeutics, Targets, and Development

  Proteomic characterization of cytoskeletal and mitochondrial class III β-tubulin

  Lucia Cicchillitti, Roberta Penci, Michela Di Michele, Flavia Filippetti, Domenico Rotilio, Maria Benedetta Donati, Giovanni Scambia and Cristiano Ferlini

  Mol Cancer Ther July 1 2008 7 (7) 2070-2079; DOI:10.1158/1535-7163.MCT-07-2370

  
  
• Research Articles: Therapeutics, Targets, and Development

  Antiangiogenic vinflunine affects EB1 localization and microtubule targeting to adhesion sites

  Stéphane Honoré, Alessandra Pagano, Géraldine Gauthier, Véronique Bourgarel-Rey, Pascal Verdier-Pinard, Karine Civiletti, Anna Kruczynski and Diane Braguer

  Mol Cancer Ther July 1 2008 7 (7) 2080-2089; DOI:10.1158/1535-7163.MCT-08-0156

  
  
• Research Articles: Therapeutics, Targets, and Development

  Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts

  Francescopaolo Di Cello, Joelle Hillion, Jeanne Kowalski, Brigitte M. Ronnett, Abimbola Aderinto, David L. Huso and Linda M.S. Resar

  Mol Cancer Ther July 1 2008 7 (7) 2090-2095; DOI:10.1158/1535-7163.MCT-07-2282

  
  
• Research Articles: Therapeutics, Targets, and Development

  Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-α-dependent and estrogen receptor-α-independent mechanisms

  Xinghua Long, Meiyun Fan, Robert M. Bigsby and Kenneth P. Nephew

  Mol Cancer Ther July 1 2008 7 (7) 2096-2108; DOI:10.1158/1535-7163.MCT-07-2350

  
  
• Research Articles: Therapeutics, Targets, and Development

  5,5′-Dibromo-bis(3′-indolyl)methane induces Krüppel-like factor 4 and p21 in colon cancer cells

  Sung Dae Cho, Sudhakar Chintharlapalli, Maen Abdelrahim, Sabitha Papineni, Shengxi Liu, Jingjing Guo, Ping Lei, Ala Abudayyeh and Stephen Safe

  Mol Cancer Ther July 1 2008 7 (7) 2109-2120; DOI:10.1158/1535-7163.MCT-07-2311

  
  
• Research Articles: Therapeutics, Targets, and Development

  Differential antiproliferative mechanisms of novel derivative of benzimidazo[1,2-α]quinoline in colon cancer cells depending on their p53 status

  Mirela Sedic, Miroslav Poznic, Peter Gehrig, Mike Scott, Ralph Schlapbach, Marijana Hranjec, Grace Karminski-Zamola, Kresimir Pavelic and Sandra Kraljevic Pavelic

  Mol Cancer Ther July 1 2008 7 (7) 2121-2132; DOI:10.1158/1535-7163.MCT-07-2261

  
  
• Research Articles: Therapeutics, Targets, and Development

  Antimigratory effect of TK1-2 is mediated in part by interfering with integrin α₂β₁

  Hyun-Kyung Kim, Dae-Shik Oh, Sang-Bae Lee, Jung-Min Ha and Young Ae Joe

  Mol Cancer Ther July 1 2008 7 (7) 2133-2141; DOI:10.1158/1535-7163.MCT-07-2405

  
  
• Research Articles: Therapeutics, Targets, and Development

  Prostate-specific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability

  Sigrid A. Rajasekaran, Jason J. Christiansen, Ingrid Schmid, Eri Oshima, Kathleen Sakamoto, Jasminder Weinstein, Nagesh P. Rao and Ayyappan K. Rajasekaran

  Mol Cancer Ther July 1 2008 7 (7) 2142-2151; DOI:10.1158/1535-7163.MCT-08-0005

  
  
• Research Articles: Therapeutics, Targets, and Development

  Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin

  Olga Kovalchuk, Jody Filkowski, James Meservy, Yaroslav Ilnytskyy, Volodymyr P. Tryndyak, Vasyl' F. Chekhun and Igor P. Pogribny

  Mol Cancer Ther July 1 2008 7 (7) 2152-2159; DOI:10.1158/1535-7163.MCT-08-0021

  
  
• Research Articles: Therapeutics, Targets, and Development

  RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis

  Robert E. Miller, Martine Roudier, Jon Jones, Allison Armstrong, Jude Canon and William C. Dougall

  Mol Cancer Ther July 1 2008 7 (7) 2160-2169; DOI:10.1158/1535-7163.MCT-08-0046

  
  
• Research Articles: Therapeutics, Targets, and Development

  Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis via p53-mediated death receptor 4 up-regulation

  Jing Zhou, Guo-Dong Lu, Chye-Sun Ong, Choon-Nam Ong and Han-Ming Shen

  Mol Cancer Ther July 1 2008 7 (7) 2170-2180; DOI:10.1158/1535-7163.MCT-08-0071

  
  
• Research Articles: Therapeutics, Targets, and Development

  Cloning and apoptosis-inducing activities of canine and feline TRAIL

  Sing Rong, Jenny H. Cai and Jennifer Andrews

  Mol Cancer Ther July 1 2008 7 (7) 2181-2191; DOI:10.1158/1535-7163.MCT-07-2139

  
  
• Research Articles: Therapeutics, Targets, and Development

  Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa

  Yang Meng, Wenhua Tang, Yao Dai, Xiaoqing Wu, Meilan Liu, Qing Ji, Min Ji, Kenneth Pienta, Theodore Lawrence and Liang Xu

  Mol Cancer Ther July 1 2008 7 (7) 2192-2202; DOI:10.1158/1535-7163.MCT-08-0333

  
  
• Research Articles: Therapeutics, Targets, and Development

  Down-regulation of X-linked inhibitor of apoptosis synergistically enhanced peroxisome proliferator-activated receptor γ ligand-induced growth inhibition in colon cancer

  Liang Qiao, Yun Dai, Qing Gu, Kwok Wah Chan, Bing Zou, Juan Ma, Jide Wang, Hui Y. Lan and Benjamin C.Y. Wong

  Mol Cancer Ther July 1 2008 7 (7) 2203-2211; DOI:10.1158/1535-7163.MCT-08-0326

  
  
• Research Articles: Therapeutics, Targets, and Development

  The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor–induced apoptosis

  Shruti M. Raja, Shuzhen Chen, Ping Yue, Timothy M. Acker, Benjamin Lefkove, Jack L. Arbiser, Fadlo R. Khuri and Shi-Yong Sun

  Mol Cancer Ther July 1 2008 7 (7) 2212-2223; DOI:10.1158/1535-7163.MCT-07-2409

  
  
• Research Articles: Therapeutics, Targets, and Development

  Key role for Bak activation and Bak-Bax interaction in the apoptotic response to vinblastine

  Meenakshi Upreti, Rong Chu, Elena Galitovskaya, Sherri K. Smart and Timothy C. Chambers

  Mol Cancer Ther July 1 2008 7 (7) 2224-2232; DOI:10.1158/1535-7163.MCT-07-2299

  
  
• Research Articles: Therapeutics, Targets, and Development

  Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids

  Margaret E. Ackerman, David Pawlowski and K. Dane Wittrup

  Mol Cancer Ther July 1 2008 7 (7) 2233-2240; DOI:10.1158/1535-7163.MCT-08-0067

  
  
• Research Articles: Therapeutics, Targets, and Development

  A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity

  Nicole Huebener, Stefan Fest, Anne Strandsby, Elke Michalsky, Robert Preissner, Yan Zeng, Gerhard Gaedicke and Holger N. Lode

  Mol Cancer Ther July 1 2008 7 (7) 2241-2251; DOI:10.1158/1535-7163.MCT-08-0109

  
  
• Research Articles: Therapeutics, Targets, and Development

  Synergistic tumoricidal effect of combined hMUC1 vaccination and hNIS radioiodine gene therapy

  Yong Hyun Jeon, Yun Choi, Sun Och Yoon, Chul Woo Kim and June-Key Chung

  Mol Cancer Ther July 1 2008 7 (7) 2252-2260; DOI:10.1158/1535-7163.MCT-08-0277